Seeking Alpha

Bayer drug hits a speed bump in the UK

  • Britain's National Institute for Health and Care Excellence gives a thumbs down to Bayer's (BAYRY) Xofigo citing a lack of evidence of effectiveness versus other therapies.
  • The drug is a radioactive agent that migrates to parts of the body exhibiting abnormal bone growth.
  • The company acquired the Norwegian firm Algeta last month for $2.9B in order to obtain the rights to the drug.
  • The ruling by NICE is draft guidance now subject to consultation.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|